ATHENS,
Greece--Dec. 22, 2005--
Acrongenomics, Inc. ( OTCBB:AGNM )
a publicly traded research and development nanobiotechnology
company pioneering the development of uniquely advanced
nano-molecular diagnostics, today announced the closing
of the 1,000,000 share private placement financing
at $4.00 per share as of Friday December 16th 2005.
Acrongenomics will use the net proceeds for the ongoing
development of the Nano-JETA platform as well as
general corporate purposes.
"The success of this financing illustrates a strong
confirmation of our approach, giving us the opportunity
to focus on delivering advanced nanotechnology research
to the life sciences industry. By putting together
our scientific excellence and strong financial base,
we have managed to complete this private placement
financing earlier than expected," said Constantine
Poulios, Acrongenomics' Vice President.
Acrongenomics also announces that it is proceeding
to obtain an independent evaluation of its technology
from a certified reference laboratory.
About Acrongenomics, Inc.
Acrongenomics, Inc. is a research and development
nanobiotechnology company pioneering the development
of uniquely advanced nano-molecular diagnostics for
the Life Sciences Industry. The Company is seeking
to establish its proprietary nanotechnology platform
as a global standard in Molecular In Vitro Diagnostics.
For further information contact us at:
Acrongenomics Inc.
Investor Relations
1-800-689-8181
email: ir@acrongen.com
website: www.acrongen.com
|
